Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | GRM5 | P41594 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2026246 | 0.90 | TSHR (0.80) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2025611 | 0.89 | TSHR (0.72) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2029999 | 0.89 | TSHR (0.70) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2025045 | 0.88 | TSHR (0.66) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2026830 | 0.88 | TSHR (0.68) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2028889 | 0.88 | TSHR (0.53) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2030742 | 0.87 | TSHR (0.67) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2025504 | 0.87 | TSHR (0.65) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2025746 | 0.87 | TSHR (0.67) | TSHRLMNAHTTMAPK1MEN1 | |
| SCHEMBL2026025 | 0.86 | TSHR (0.66) | TSHRLMNAHTTMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | claimed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
| WO-2008003861-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | EPX, PGLS, ENPEP | TSHR 2305/4885LMNA 1439/4885HTT 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.